Legal & General Group Plc Buys Shares of 57,243 BeOne Medicines Ltd. – Sponsored ADR $ONC

Legal & General Group Plc bought a new position in shares of BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) during the 2nd quarter, according to its most recent 13F filing with the SEC. The fund bought 57,243 shares of the company’s stock, valued at approximately $13,857,000. Legal & General Group Plc owned approximately 0.05% of BeOne Medicines as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also made changes to their positions in the company. Primecap Management Co. CA acquired a new stake in shares of BeOne Medicines in the second quarter valued at about $1,231,720,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in BeOne Medicines during the second quarter worth about $73,347,000. Candriam S.C.A. purchased a new position in BeOne Medicines in the second quarter valued at about $67,852,000. Artisan Partners Limited Partnership purchased a new position in BeOne Medicines in the second quarter valued at about $65,396,000. Finally, M&G PLC acquired a new stake in shares of BeOne Medicines during the 2nd quarter valued at approximately $41,189,000. 48.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other BeOne Medicines news, SVP Chan Henry Lee sold 10,671 shares of the firm’s stock in a transaction dated Wednesday, October 8th. The shares were sold at an average price of $350.40, for a total transaction of $3,739,118.40. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Lai Wang sold 5,000 shares of the business’s stock in a transaction that occurred on Tuesday, September 9th. The shares were sold at an average price of $350.06, for a total transaction of $1,750,300.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 81,254 shares of company stock worth $27,971,587 in the last 90 days. 6.62% of the stock is currently owned by corporate insiders.

BeOne Medicines Stock Down 0.0%

Shares of NASDAQ:ONC opened at $340.61 on Friday. The company has a quick ratio of 2.17, a current ratio of 2.39 and a debt-to-equity ratio of 0.03. The company has a market capitalization of $40.38 billion, a P/E ratio of 667.86 and a beta of 0.31. BeOne Medicines Ltd. – Sponsored ADR has a 52-week low of $170.99 and a 52-week high of $385.22. The stock’s fifty day simple moving average is $332.72 and its 200-day simple moving average is $299.13.

Analyst Ratings Changes

ONC has been the subject of several research analyst reports. JPMorgan Chase & Co. raised their price objective on BeOne Medicines from $345.00 to $385.00 and gave the company an “overweight” rating in a research note on Wednesday, October 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of BeOne Medicines in a report on Wednesday, October 8th. Citigroup raised their price target on BeOne Medicines from $399.00 to $405.00 and gave the company a “buy” rating in a research report on Monday, November 10th. Zacks Research lowered shares of BeOne Medicines from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 28th. Finally, Guggenheim raised their target price on shares of BeOne Medicines from $350.00 to $365.00 and gave the company a “buy” rating in a report on Thursday, August 7th. Twelve research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $365.79.

About BeOne Medicines

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.